Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.60 |
| ▸ | FAP | Q12884 | 5/20 | 0.53 |
| ▸ | PREP | P48147 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324091 | 0.84 | DPP4 (0.64) | DPP4FAPPREPACESMN1; SMN2 | |
| SCHEMBL29359148 | 0.84 | DPP4 (0.63) | DPP4FAPPREPACESMN1; SMN2 | |
| SCHEMBL22811103 | 0.81 | ACE (0.54) | DPP4FAPPREPACEDPP7 | |
| SCHEMBL29360006 | 0.81 | F2 (0.48) | DPP4FAPPREPSMN1; SMN2 | |
| SCHEMBL30182791 | 0.80 | DPP4 (0.58) | DPP4FAPPREP | |
| SCHEMBL30182765 | 0.79 | DPP4 (0.62) | DPP4FAPPREPSMN1; SMN2NPC1 | |
| SCHEMBL30182879 | 0.79 | RAB9A (0.54) | SMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL22209470 | 0.78 | PREP (0.69) | DPP4FAPPREPACESMN1; SMN2 | |
| SCHEMBL22811348 | 0.78 | PREP (0.69) | DPP4FAPPREPACESMN1; SMN2 | |
| SCHEMBL31324097 | 0.77 | DPP4 (0.55) | DPP4FAPPREPSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |